Population studies of wild-type and drug-resistant mutant HIV in mixed infections

Virology

Volumn 236, Issue 1, 1997, Pages 85-94

  Rayner, Marlene M ^a   Cordova, Beverly ^a   Jackson, David A ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; AZEPINE DERIVATIVE; DRUG DERIVATIVE; EFAVIRENZ; MOZENAVIR; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UREA;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MIXED INFECTION; NONHUMAN; POPULATION DYNAMICS; PRIORITY JOURNAL; VIRUS MUTANT; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGICAL EXAMINATION; TIME; VIROLOGY; VIRUS CULTURE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AZEPINES; DRUG RESISTANCE, MICROBIAL; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZINES; PLAQUE ASSAY; POPULATION DYNAMICS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; UREA;

EID: 0031571885     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8620     Document Type: Article

References (32)

1. Balzarini, J., Karlsson, A., Perez-Perez, M.-J., Vrang, L., Walbers, J., Zhang, H., Oberg, B., Mieke, A., Camarasa, M.-J., and De Clerq, E. (1993). HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192, 248-253.
2. Byrnes, V. W., Sardana, V. V., Schleif, W. A., Condra, J. H., Waterbury, J. A., Wolfgang, J. A., Long, W. J., Schneider, C. L., Schlabach, A. J., Wolanski, B. S., Graham, D. J., Gotlib, L., Rhodes, A., Titus, D. L., Roth, E., Blahy, O. M., Quintero, J. C., Staszewski, S., and Emini, E. A. (1993). Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type I reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1576-1579.
3. Coffin, J. M. (1995). HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
4. Condra, J. H., Schleif, W. S., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Rothe, E., Shivaprokash, M., Titus, D., Yang, T., Toppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
5. Croteau, G., Doyon, L., Thibeault, D., McKercher, G., Pilote, L., and Lamarre, D. (1997). Impaired fitness of human immunodeficiency virus type I variants with high-level resistance to protease inhibitors. J Virol. 71, 1089-1096.
6. Darke, P. L., Nutt, R. F., Brady, S. F., Gaesky, V. M., Cicerone, T., Leu, C-T., Lumma, P. K., Freidinger, R. M., Veber, D. F., and Sigal, I. S. (1988). HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156, 297-303.
7. Debouck, C., and Metcalf, B. W. (1990). Human immunodeficiency protease: A target for AIDS therapy. Drug Dev. Res. 21, 1-17.
8. DeClerq, E. (1993). HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type I that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13(3), 229-258.
9. El-Farrash, M. A., Kuroda, M. J., Kitazaki, T., Masuda, T., Kato, K., Hatanaka, M., and Harada, S. (1994). Generation and characterization of a human immunodeficiency virus type I (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol. 68, 233-239.
10. Erickson-Viitanen, S., Manfredi, J, Viitanen, P., Tribe, D. E., Tritch, R., Hutchison, C. A. III, Loeb, D. D., and Swanstrom, R. (1989). Cleavage of HIV-1 gag polyprotein synthesized in vitro: Sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5, 577-591.
11. Gulnik, S. V., Suvorov, L. I., Liu, B., Anderson, B., Mitsuya, H., and Erickson, J. W. (1995). Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282-9287.
12. Harada, S., Koyawagi, Y., and Yamamoto, N. (1985). Infection of HTLV-III/LAV in HTLV-I-carrying cells MT2 and MT4 and application in plaque assay. Science 229, 563-566.
13. Havlir, D. V., Eastman, S., Gamst, A., and Richman, D. D. (1996). Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70(11), 7894-7899.
14. Hodge, C. N., Aldrich, P. E., Fernandez, C. H., Otto, M. J., Rayner, M. M., Wong, Y. N., and Erickson-Viitanen, S. (1994). Studies on orally available inhibitors of HIV protease. Peptidyl aldehydes and trifluoromethyl ketones. Antiviral Chem. Chemother. 5(4), 257-262.
15. Hodge, C. N., Aldrich, P., Bacheler, L., Chang, C-H., Eyermann, C. J., Garber, S., Grubb, Jackson, D. A., Jadhav, P. K., Korant, B., Lam, P. Y. S., M., Maurin, M., Meek, J. L., Otto, M. J., Rayner, M. M., Reid, C., Sharpe, T. R., Shum, L., Winslow, D., and Erickson-Viitanen, S. (1996). Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem. Biol. 3, 301-314.
16. Jacobsen, H., Yasagil, K., Winslow, D. L., Craig, C., Krohn, A., Duncan, I. A., and Mous, J. (1995). Characterization of human immunodeficiency virus type I mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527-534.
17. Kenealy, W., Reed, D., Cybulski, R., Tribe, D., Taylor, P., Stevens, C., Matthews, T., and Petteway, S. (1987). Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens. AIDS Res. Hum. Retroviruses 3(1), 95-105.
18. Kohl, N. E., Emini, E. A., Schlief, W. A., Davis, L. J., Hermbach, J. C., Dixon, R. A. F., Scolnick, E. M., and Sigel, I. S. (1988). Active human immunodeficiency virus is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686-4690.
19. Kuroda, M. J., El-Farrash, M. A., Choudhury, S., and Harada, S. (1995). Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. Virology 210, 212-216.
20. Lech, W. J., Wang, G., Yang, L. Y., Chee, Y., Dorman, K., McCrae, D., Lazzeroni, L. C., Erickson, J. W., Sinsheimer, J. S., Kaplan, A. H. (1996). In vivo sequence diversity of the protease of human immunodeficiency virus type I: Presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70, 2038-2043.
21. Lin, Y., Lin, X., Hong, L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shah, M., Dunn, B. M., and Tang, J. (1995). Effect of point mutation on kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance. Biochemistry 34, 1143-1152.
22. Mascher, B., Darby, G., Palus, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., Furfine, E. S. (1996). Human immunodeficiency virus mutations in the viral protease that confer resistance to sacquinavir increase the dissociation rate constant of the protease-sacquinavir complex. J. Biol. Chem. 271(52), 33231-33235.
23. Markowitz, M., Mo, H., Kempf, D. J., Norbeck, D. W., Bhat, T. N., Erickson, J. W., and Ho, D. D. (1995). Selection and analysis of human immunodeficiency virus type 1 variants with increase resistance to ABT-538: A novel protease inhibitor. J. Virol. 69, 701-706.
24. Mellors, J. W., Larder, B. A., and Schnazi, R. F. (1995). Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Intnl. Antiviral News 41, 446-451.
25. Rayner, M. M., Cordova, B. C., Meade, R. P., Aldrich, P. E., Jadhav, Ru, Y., and Lam, P. Y-S. (1994). DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistantly blocks intracellular processing of HIV GAG polyprotein. Antimicrob. Agents Chemother. 38, 1635-1640.
26. Smallheer, J. M., Otto, M. J., Amarli-Ly, C. A., Earl, R. A., Myers, M. J., Pennev, P., Montefiori, D. C., and Wuonola, M. A. (1993). Synthesis and the anti-HIV activity of a series of 2-indolinones and related analogues. Antiviral Chem. Chemother. 4, 27-39.
27. Tang, J., and Hartsuck, J. A. (1995). A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases. FEBS Lett. 367, 112-116.
28. Tisdale, M., Myers, R. E., Maschera, B., Parry, N. R., Oliver, N. M., and Blair, E. D. (1995). Cross resistance analysis of human immunodeficiency virus type I variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39, 1704-1710.
29. Winslow, D. L., Anton, E. D., Horlick, R. A., Zagursky, R. J., Tritch, R. J., Scarnati, H., Ackerman, K., and Bacheler, L. T. (1994). Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem. Biophys. Res. Commun. 205, 1651-1657.
30. Winslow, D. L., and Otto, M. J. (1995). HIV protease inhibitors. AIDS 9(suppl A), 183-192.
31. Wlodawer, A., and Erickson, J. W. (1993). Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62, 543-585.
32. Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., Carroll, S. S., Pettibone, D. J., O'Brien, J. A., Ball, R. G., Balani, S. K., Lin, J. H., Chen, I-W., Schlief, W. A., Sardana, V. V., Long, W. J., Byrnes, V. W., and Emini, E. A. (1995). L-743,726 (DMP 266): a novel highly potent nucleoside inhibitor of the human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. 39, 2602-2605.